Every year on September 21, we celebrate World Alzheimer's Day to battle the stigma associated with dementia and Alzheimer's disease and increase public awareness of these disorders
Because the study was only observational, it cannot ascertain cause and effect between the drug and the impact on dementia risk. The scientists have called for clinical trials to now be carried out
US researchers have developed a novel Artificial Intelligence-based tool that has shown 90 per cent accuracy in detecting Alzheimer's disease from routinely collected clinical brain images
Scientists have developed a blood-based test that could be used to predict the risk of Alzheimer's disease up to 3.5 years before clinical diagnosis. The research, published in the journal Brain, supports the idea that components in the human blood can modulate the formation of new brain cells, a process termed neurogenesis. Neurogenesis occurs in an important part of the brain called the hippocampus that is involved in learning and memory. While Alzheimer's disease affects the formation of new brain cells in the hippocampus during the early stages of the disease, previous studies have only been able to study neurogenesis in its later stages through autopsies. To understand the early changes, researchers collected blood samples over several years from 56 individuals with Mild Cognitive Impairment (MCI), a condition where someone will begin to experience a worsening of their memory or cognitive ability. While not everyone experiencing MCI goes on to develop Alzheimer's disease, tho
FDA cautioned that genetic health risk tests are intended to provide genetic risk information